D. E. Shaw & Co., Inc. Vanda Pharmaceuticals Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 559,798 shares of VNDA stock, worth $2.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

559,798

Holding current value

$2.68 Million

% of portfolio

0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.61 - $6.34 $612,844 - $842,826	-132,938 Reduced 19.19%	559,798 $2.63 Million
Q2 2024 Aug 14, 2024	SELL	$3.91 - $6.5 $4.34 Million - $7.22 Million	-1,110,106 Reduced 61.58%	692,736 $3.91 Million
Q1 2024 May 15, 2024	SELL	$3.47 - $4.61 $1.07 Million - $1.43 Million	-309,283 Reduced 14.64%	1,802,842 $7.41 Million
Q4 2023 Feb 14, 2024	BUY	$3.38 - $4.58 $555,624 - $752,887	164,386 Added 8.44%	2,112,125 $8.91 Million
Q3 2023 Nov 14, 2023	BUY	$4.28 - $6.57 $2.85 Million - $4.38 Million	666,261 Added 51.99%	1,947,739 $8.41 Million
Q2 2023 Aug 14, 2023	SELL	$5.9 - $6.95 $481,552 - $567,252	-81,619 Reduced 5.99%	1,281,478 $8.44 Million
Q1 2023 May 15, 2023	BUY	$6.18 - $7.99 $1.65 Million - $2.13 Million	266,662 Added 24.32%	1,363,097 $9.26 Million
Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $1.33 Million - $2.12 Million	193,006 Added 21.36%	1,096,435 $8.1 Million
Q3 2022 Nov 14, 2022	BUY	$9.44 - $11.76 $485,697 - $605,063	51,451 Added 6.04%	903,429 $8.93 Million
Q2 2022 Aug 15, 2022	BUY	$9.31 - $11.84 $1.7 Million - $2.16 Million	182,831 Added 27.32%	851,978 $9.29 Million
Q1 2022 May 16, 2022	BUY	$10.84 - $16.55 $467,063 - $713,089	43,087 Added 6.88%	669,147 $7.57 Million
Q4 2021 Feb 14, 2022	SELL	$15.69 - $21.14 $3.14 Million - $4.22 Million	-199,840 Reduced 24.2%	626,060 $9.82 Million
Q3 2021 Nov 15, 2021	SELL	$15.35 - $21.27 $851,111 - $1.18 Million	-55,447 Reduced 6.29%	825,900 $14.2 Million
Q2 2021 Aug 16, 2021	BUY	$15.71 - $21.51 $1.99 Million - $2.73 Million	126,918 Added 16.82%	881,347 $19 Million
Q1 2021 May 17, 2021	BUY	$13.42 - $20.28 $4.59 Million - $6.94 Million	341,970 Added 82.91%	754,429 $11.3 Million
Q4 2020 Feb 16, 2021	SELL	$9.77 - $13.81 $1.27 Million - $1.8 Million	-130,082 Reduced 23.98%	412,459 $5.42 Million
Q3 2020 Nov 16, 2020	SELL	$9.32 - $12.02 $1.71 Million - $2.2 Million	-183,363 Reduced 25.26%	542,541 $5.24 Million
Q2 2020 Aug 14, 2020	BUY	$9.66 - $12.02 $1.11 Million - $1.38 Million	114,892 Added 18.8%	725,904 $8.3 Million
Q1 2020 May 15, 2020	BUY	$7.5 - $16.8 $3.77 Million - $8.45 Million	503,119 Added 466.31%	611,012 $6.33 Million
Q4 2019 Feb 14, 2020	SELL	$12.38 - $17.47 $2.24 Million - $3.16 Million	-181,070 Reduced 62.66%	107,893 $1.77 Million
Q3 2019 Nov 14, 2019	BUY	$12.27 - $15.79 $3.29 Million - $4.24 Million	268,413 Added 1306.15%	288,963 $3.84 Million
Q2 2019 Aug 14, 2019	SELL	$13.37 - $18.85 $137,644 - $194,060	-10,295 Reduced 33.38%	20,550 $290,000
Q1 2019 May 15, 2019	BUY	$17.59 - $31.05 $542,563 - $957,737	30,845 New	30,845 $568,000
Q4 2018 Feb 14, 2019	SELL	$18.97 - $31.47 $2.26 Million - $3.74 Million	-118,872 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$18.25 - $23.0 $4.05 Million - $5.11 Million	-222,024 Reduced 65.13%	118,872 $2.73 Million
Q2 2018 Aug 14, 2018	BUY	$13.95 - $19.15 $2.48 Million - $3.4 Million	177,621 Added 108.79%	340,896 $6.49 Million
Q1 2018 May 15, 2018	SELL	$14.05 - $20.2 $43,793 - $62,963	-3,117 Reduced 1.87%	163,275 $2.75 Million
Q4 2017 Feb 14, 2018	SELL	$12.85 - $18.1 $512,727 - $722,208	-39,901 Reduced 19.34%	166,392 $2.53 Million
Q3 2017 Nov 14, 2017	BUY	$15.4 - $18.85 $3.18 Million - $3.89 Million	206,293	206,293 $3.69 Million

Others Institutions Holding VNDA

# of Institutions

161

Shares Held

45.2M

Call Options Held

165K

Put Options Held

33.6K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $270M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account